BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 16875900)

  • 21. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of RAAS Blockers on Atrial Fibrillation Prophylaxis: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Chaugai S; Meng WY; Ali Sepehry A
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):388-404. PubMed ID: 26817632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
    Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Yusuf S
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
    Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
    Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials.
    Madrid AH; Peng J; Zamora J; Marín I; Bernal E; Escobar C; Muños-Tinoco C; Rebollo JM; Moro C
    Pacing Clin Electrophysiol; 2004 Oct; 27(10):1405-10. PubMed ID: 15511250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Unsatisfactory results of upstream therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for the prevention of recurrent atrial fibrillation].
    Disertori M; Zeni P; Quintarelli S; Bonmassari R
    G Ital Cardiol (Rome); 2010 Nov; 11(11):829-34. PubMed ID: 21348320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of renin blockers in the prevention of diabetes.
    Alkhenizan AH; Alswes MA
    Saudi Med J; 2007 Jan; 28(1):91-5. PubMed ID: 17206297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.
    L'Allier PL; Ducharme A; Keller PF; Yu H; Guertin MC; Tardif JC
    J Am Coll Cardiol; 2004 Jul; 44(1):159-64. PubMed ID: 15234426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renin-angiotensin system inhibitors prevent the recurrence of atrial fibrillation: a meta-analysis of randomized controlled trials.
    Han M; Zhang Y; Sun S; Wang Z; Wang J; Xie X; Gao M; Yin X; Hou Y
    J Cardiovasc Pharmacol; 2013 Oct; 62(4):405-15. PubMed ID: 23921300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pathophysiology of the renin-angiotensin-system in atrial fibrillation].
    Heusch G; Schulz R
    Dtsch Med Wochenschr; 2006 Apr; 131(15):817-20. PubMed ID: 16607602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure.
    Aksnes TA; Flaa A; Strand A; Kjeldsen SE
    J Hypertens; 2007 Jan; 25(1):15-23. PubMed ID: 17143167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.
    Salehian O; Healey J; Stambler B; Alnemer K; Almerri K; Grover J; Bata I; Mann J; Matthew J; Pogue J; Yusuf S; Dagenais G; Lonn E;
    Am Heart J; 2007 Sep; 154(3):448-53. PubMed ID: 17719288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.
    Vermes E; Tardif JC; Bourassa MG; Racine N; Levesque S; White M; Guerra PG; Ducharme A
    Circulation; 2003 Jun; 107(23):2926-31. PubMed ID: 12771010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
    Phillips CO; Kashani A; Ko DK; Francis G; Krumholz HM
    Arch Intern Med; 2007 Oct; 167(18):1930-6. PubMed ID: 17923591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The renin-angiotensin system: a therapeutic target in atrial fibrillation.
    Patlolla V; Alsheikh-Ali AA; Al-Ahmad AM
    Pacing Clin Electrophysiol; 2006 Sep; 29(9):1006-12. PubMed ID: 16981926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does treatment with ACE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation after dual chamber pacemaker implantation?
    Williams SG; Connelly DT; Jackson M; Bennett A; Albouaini K; Todd DM
    Europace; 2005 Nov; 7(6):554-9. PubMed ID: 16216757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.
    Savelieva I; Kakouros N; Kourliouros A; Camm AJ
    Europace; 2011 Mar; 13(3):308-28. PubMed ID: 21345926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focus on renin-angiotensin system modulation and atrial fibrillation control after GISSI AF results.
    Durin O; Pedrinazzi C; Inama G
    J Cardiovasc Med (Hagerstown); 2010 Dec; 11(12):912-8. PubMed ID: 20729747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.